AVIR Q1 2023 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AVIRAtea Pharmaceuticals, Inc.

$501M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$29M

Operating Income

-$42M

Net Income

-$35M

EPS (Diluted)

$-0.43

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$30M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$638M

Total Liabilities

$20M

Stockholders' Equity

$618M

Cash & Equivalents

$183M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$29M	-$30M	+2.3%
Operating Income	-$42M	-$42M	+1.4%
Net Income	-$35M	-$42M	+15.7%